Biotechs often need several years to realize their visions, even after they have a drug approved for the first time. There's typically plenty of upside in store for enterprising and patient investors.Here are two such opportunities that are ripe for buying today, provided that you're willing to hold on to your shares for at least five years.1. CRISPR TherapeuticsWith a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (CRSP 0.85%) has an impressive resume already, but i ...